Enhancing sepsis biomarker development: key considerations from public and private perspectives
Jean‐François Llitjos(Université Paris Cité), Didier Payen(Délégation Paris 7), Marc Bonneville(Institut Mérieux (France)), Adrienne G. Randolph(The Centers), Marcin F. Osuchowski(Ludwig Boltzmann Institute for Traumatology, The Research Center in Cooperation with AUVA), Jesús Rodríguez-Manzano(Fleming College), Brendon P. Scicluna(Academic Medical Center), Bruno François(Inserm), Stephan Witte(MerLion Pharma (Germany)), Enitan D. Carrol(University of Liverpool)
Cited by 81
Related Papers
Sepsis in European intensive care units: Results of the SOAP study*
|Critical Care Medicine|2006|2.9k
Assessment of the worldwide burden of critical illness: the Intensive Care Over Nations (ICON) audit
|The Lancet Respiratory Medicine|2014|1.3k
Surviving Sepsis Campaign International Guidelines for the Management of Septic Shock and Sepsis-Associated Organ Dysfunction in Children
|Pediatric Critical Care Medicine|2020|1.2k
The SOFA score—development, utility and challenges of accurate assessment in clinical trials
|Critical Care|2019|976